Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Acres

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Cancer Immunology, Immunotherapy : CII|November 20, 2002
The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancerStephane Paul, Etienne Regulier, Yves Poitevin, et al.
Current Opinion in Molecular Therapeutics|March 12, 2004
Therapeutic cancer vaccinesBruce Acres, Stephane Paul, Helene Haegel-Kronenberger, et al.
Cancer Gene Therapy|October 9, 2004
Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-LBastien Calmels, Stéphane Paul, Nicolas Futin, et al.
The Journal of Clinical Investigation|September 8, 2007
Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomasMirjana Urosevic, Kazuyasu Fujii, Bastien Calmels, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 31, 2004
Gene-based vaccines and immunotherapeuticsMargaret Liu, Bruce Acres, Jean-Marc Balloul, et al.
Cancer Research|October 19, 2005
Fusokine interleukin-2/interleukin-18, a novel potent innate and adaptive immune stimulator with decreased toxicityBruce Acres, Murielle Gantzer, Christelle Remy, et al.
Cancer Gene Therapy|April 18, 2002
Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in miceJan Zaloudik, Weiping Li, Lutz Jacob, et al.
Viral Immunology|December 27, 2007
Specific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particlesStéphane Paul, Michel Geist, Karine Dott, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 5, 2008
Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanomaReinhard Dummer, Christoph Rochlitz, Thierry Velu, et al.
The Journal of Gene Medicine|August 5, 2003
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancerChristoph Rochlitz, Robert Figlin, Patrick Squiban, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Cancer Immunology, Immunotherapy : CII|November 20, 2002
The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancerStephane Paul, Etienne Regulier, Yves Poitevin, et al.
Current Opinion in Molecular Therapeutics|March 12, 2004
Therapeutic cancer vaccinesBruce Acres, Stephane Paul, Helene Haegel-Kronenberger, et al.
Cancer Gene Therapy|October 9, 2004
Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-LBastien Calmels, Stéphane Paul, Nicolas Futin, et al.
The Journal of Clinical Investigation|September 8, 2007
Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomasMirjana Urosevic, Kazuyasu Fujii, Bastien Calmels, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 31, 2004
Gene-based vaccines and immunotherapeuticsMargaret Liu, Bruce Acres, Jean-Marc Balloul, et al.
Cancer Research|October 19, 2005
Fusokine interleukin-2/interleukin-18, a novel potent innate and adaptive immune stimulator with decreased toxicityBruce Acres, Murielle Gantzer, Christelle Remy, et al.
Cancer Gene Therapy|April 18, 2002
Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in miceJan Zaloudik, Weiping Li, Lutz Jacob, et al.
Viral Immunology|December 27, 2007
Specific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particlesStéphane Paul, Michel Geist, Karine Dott, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 5, 2008
Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanomaReinhard Dummer, Christoph Rochlitz, Thierry Velu, et al.
The Journal of Gene Medicine|August 5, 2003
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancerChristoph Rochlitz, Robert Figlin, Patrick Squiban, et al.
Pageof 3